Twitter | Search | |
Sylvie Vullioud
Swiss citizen concerned by OA & ORD issues : policies, business transparency, costs, copyright, reproducibility. RT may not reflect my opinion.
5,182
Tweets
244
Following
246
Followers
Tweets
Sylvie Vullioud 15h
Replying to @SylvieVullioud
I'm trying to understand if consent is needed in Switzerland for a retrospective study using personal data that were not necessarily designed for the study. Is it legal? Thanks in advance for you explanation and help.
Reply Retweet Like
Sylvie Vullioud 15h
Replying to @SylvieVullioud
Which personal data were deidentified to build the database by Surgisphere corporation? Were patient included in one of 3 clinical trials in Switzerland, or from patient treated with HQ because nothing was to lose?
Reply Retweet Like
Sylvie Vullioud 15h
Frank Ruschitzka is a Swiss based researcher. Could someone tell me if Swiss patient data were used in the Lancet study, he is one of author?
Reply Retweet Like
Sylvie Vullioud retweeted
Le Doc 17h
Pas sûr que ça fasse taire les critiques, mais un premier pas.
Reply Retweet Like
Sylvie Vullioud retweeted
Annick Chevillot 🌊 17h
Quelle science a guidé l' pour établir des recommandations pendant l'épidémie de ? Si les études ne sont pas la seule base décisionnelle, elles sont importantes. La liste complète à découvrir sur
Reply Retweet Like
Sylvie Vullioud 20h
L’étude du «Lancet» sur l’efficacité de l’hydroxychloroquine mise en doute via
Reply Retweet Like
Sylvie Vullioud retweeted
Mathieu Saby May 28
Il y aura vraiment une thèse à faire en sociologie des sciences ou en IST sur la publication scientifique au temps du coronavirus...
Reply Retweet Like
Sylvie Vullioud May 28
Replying to @gap_id
Et aussi en lien avec mon mail:
Reply Retweet Like
Sylvie Vullioud May 28
Questions raised over hydroxychloroquine study which caused WHO to halt trials for Covid-19
Reply Retweet Like
Sylvie Vullioud May 28
Chloroquine : “Je ne suis pas pro-Raoult mais l'étude publiée par The Lancet, c'est une merde”, lance le Pr. Froguel - France 3 Hauts-de-France
Reply Retweet Like
Sylvie Vullioud May 28
Replying to @gap_id
Reply Retweet Like
Sylvie Vullioud May 28
I wish that swissuniversities, library consortium, and display useful efficient guidelines for authors for this situation. Thank you.
Reply Retweet Like
Sylvie Vullioud May 28
Especially because the R&P deal do not comprise Cell Press and Lancet journals, how can Swiss researchers comply with OA guidelines?
Reply Retweet Like
Sylvie Vullioud May 28
I would like to know about embargo period of Elsevier journals not in the R&P agreement? SInce asks for 6 months, and most Elsevier subscription journals have 12 months embargo, it is still complicated situation for researchers.
Reply Retweet Like
Sylvie Vullioud retweeted
Elisabeth #StayingAtHome #StayingAlive Bik May 28
Questions raised over hydroxychloroquine study which caused WHO to halt trials for Covid-19
Reply Retweet Like
Sylvie Vullioud May 28
Replying to @gap_id @VilmenCeline
oups, p.3 (...) (iv) undertake reasonable efforts to ensure that Accepted Manuscripts bear a CC BY-NC-ND license and link back to the Published Journal Article/Published Book Chapter on ScienceDirect;
Reply Retweet Like
Sylvie Vullioud May 28
Replying to @gap_id @VilmenCeline
p.2 en bas: In connection with the storage ofData from the PubLished Journal Articles/Published Book Chapters from Autbors in the Subscriber's lnstitutionaJ Repository, the Subscriber will:
Reply Retweet Like
Sylvie Vullioud May 28
p.3 In connection with the storage ofData from the PubLished Journal Articles/Published Book Chapters from Autbors in the Subscriber's lnstitutionaJ Repository, the Subscriber will:
Reply Retweet Like
Sylvie Vullioud May 28
Replying to @gap_id @VilmenCeline
Tu parles de la version finale. Je parle de la version du manuscrit accepté ou terme que je n'aime pas, post-print!
Reply Retweet Like
Sylvie Vullioud May 28
Replying to @gap_id
Et aussi: commentaires sur Facebook, sur le problème de la licence imposée sur le manuscript accepté, qui sous-entend un transfert du droit d'auteur exclusif à Elsevier
Reply Retweet Like